NCT02392455View on ClinicalTrials.gov

VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)

CompletedOBSERVATIONAL
Enrollment

817

Participants

Timeline

Start Date

March 23, 2015

Primary Completion Date

July 23, 2025

Study Completion Date

July 23, 2025

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

treatment

Docetaxel plus nintedanib until progression or intolerability

Trial Locations (1)

Unknown

Multiple Locations

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY